The National Center for Advancing Translational Sciences awarded a purchase order to Gempharmatech LLC for $89,040 on September 11, 2026, to evaluate a lead NNMT inhibitor in humanized mouse models of chronic kidney disease.
The order procures three services: recovery and production of 50 male hNNMT homozygous mice from cryopreserved sperm via in vitro fertilization and breeding; efficacy study of the lead NNMT inhibitor in an adenine diet-induced chronic kidney disease model; and efficacy study in a High-Sugar High-Fat Diet combined with Streptozotocin-induced diabetic kidney disease model. Work is performed at NIH/NCATS in Rockville, Maryland. Period of performance runs August 31, 2026, through August 30, 2027. The procurement was awarded on a sole-source basis under FAR 6.302-3(a)(2)(ii) because Gempharmatech developed the humanized NNMT mouse model under prior NIH-funded work and maintains the cryopreserved sperm and breeding resources necessary to regenerate the colony. NAICS code 541714 applies.